Abstract: The present disclosure provides compounds of Formula I or II. Compounds of Formula I or II may be used in pharmaceutical formulations, and may be used for modulating glucocorticoid receptors.

Abstract: The present disclosure provides compounds of Formula I or II. Compounds of Formula I or II may be used in pharmaceutical formulations, and may be used for modulating glucocorticoid receptors.

Abstract: The present disclosure provides for compounds of the general Formula (I) wherein R1a, R1b, R2, R3, R4, R5, R6, R7, R8, and Ring A have any of the values defined in the specification, and pharmaceutically acceptable salts thereof.

Abstract: The present disclosure provides compounds of Formula I, Ia, Ib, Ib-1, Ib-2, Ic, Ic-1, Id-1, and Id-2. Compounds of Formula I, Ia, Ib, Ib-1, Ib-2, Ic, Ic-1, Id-1, and Id-2 may be used in pharmaceutical formulations, and may be used for modulating glucocorticoid receptors.

Abstract: The present disclosure provides piperazine substituted fused azadecalin compounds of Formula J, I, Ia, Ib, Ib-1, Ib-2, Ic and Id for use in pharmaceutical formulations, and for modulating glucocorticoid receptors.

Abstract: The present disclosure provides compounds of Formula I or II. Compounds of Formula I or II may be used in pharmaceutical formulations, and may be used for modulating glucocorticoid receptors.

Abstract: The disclosures herein relate to novel compounds of formula (1) and salts thereof, wherein V; W; X; Y; Z; R1; R2; R3; R4 and R5 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of neurological or psychiatric disorders associated with orexin receptors.

Abstract: The disclosures herein relate to novel compounds of formula (I): and salts thereof, wherein W; X; Y; Z; R1; R2; R3 and R4 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of neurological or psychiatric disorders associated with orexin receptors.

Abstract: The disclosures herein relate to novel compounds of formula (1) and salts thereof, wherein X; Y; R1; R2; R3; R4; R5; R6; R7 and R8 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of neurological or psychiatric disorders associated with orexin receptors.

Abstract: Example implementations relate to a storage system. An example implementation includes a storage system including a controller coupled to a storage medium. The controller is to receive block priority information from a file system via a communication agent. The block priority information and the file system are associated with the storage medium. Based on the block priority information, the controller is to selectively perform an operation on the storage medium. The operation includes a reconstruction operation, a data scrubbing operation, and a data migration operation.

Abstract: Compounds are provided that modulate the glucagon-like peptide 1 (GLP-1) receptor, as well as methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds can act as modulators or potentiators of GLP-1 receptor on their own, or with incretin peptides such as GLP-1(7-36) and GLP-1(9-36), or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where “” represents either or both the R and S form of the compound): where A, B, C, Y1, Y2, Z, R1, R2, R3, R4, R5, W1, n, p and q are as defined herein.

Abstract: Compounds are provided that modulate the glucagon-like peptide 1 (GLP-1) receptor, as well as methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds can act as modulators or potentiators of GLP-1 receptor on their own, or with incretin peptides such as GLP-1(7-36) and GLP-1(9-36), or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where “” represents either or both the R and S form of the compound): where A, B, C, Y1, Y2, Z, R1, R2, R3, R4, R5, W1, n, p and q are as defined herein.

Abstract: Compounds are provided that modulate the glucagon-like peptide 1 (GLP-1) receptor, as well as methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds can act as modulators or potentiators of GLP-1 receptor on their own, or with incretin peptides such as GLP-1(7-36) and GLP-1(9-36), or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where “” represents either or both the R and S form of the compound): where A, B, C, Y1, Y2, Z, R1, R2, R3, R4, R5, W1, n, p and q are as defined herein.

Abstract: Example implementations relate to a storage system. An example implementation includes a storage system including a controller coupled to a storage medium. The controller is to receive block priority information from a file system via a communication agent. The block priority information and the file system are associated with the storage medium. Based on the block priority information, the controller is to selectively perform an operation on the storage medium. The operation includes a reconstruction operation, a data scrubbing operation, and a data migration operation.

Abstract: Compounds are provided that modulate the glucagon-like peptide 1 (GLP-1) receptor, as well as methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds can act as modulators or potentiators of GLP-1 receptor on their own, or with incretin peptides such as GLP-1(7-36) and GLP-1(9-36), or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where “” represents either or both the R and S form of the compound): where A, B, C, Y1, Y2, Z, R1, R2, R3, R4, R5, W1, n, p and q are as defined herein.

Abstract: Systems and methods for presenting managed data from one or more applications are invented and disclosed. A data storage management system comprises a data store, a data storage manager, and a graphical user interface. The data storage manager is communicatively coupled to the data store and configured to allocate and use logical and physical storage elements of the data store via an application instance. The graphical user interface exposes data storage in application specific storage units. A method for managing data comprises coupling a data store to one or more applications, allocating storage on the data store in accordance with respective storage requirements expressed as an application instance associated with each of the one or more applications, and using a graphical user interface to expose the data store in application storage units associated with the one or more applications.

Abstract: Systems and methods for presenting managed data from one or more applications are invented and disclosed. A data storage management system comprises a data store, a data storage manager, and a graphical user interface. The data storage manager is communicatively coupled to the data store and configured to allocate and use logical and physical storage elements of the data store via an application instance. The graphical user interface exposes data storage in application specific storage units. A method for managing data comprises coupling a data store to one or more applications, allocating storage on the data store in accordance with respective storage requirements expressed as an application instance associated with each of the one or more applications, and using a graphical user interface to expose the data store in application storage units associated with the one or more applications.

Abstract: Systems and methods for data storage management are invented and disclosed. A data storage management system comprises an accessible data store and a data storage manager. The data storage manager is communicatively coupled to the data store and configured to allocate and use logical and physical storage elements of the data store via an application instance that exposes data storage in application specific storage units. A method for managing data comprises coupling a data store to one or more applications, allocating storage on the data store in accordance with respective optimized/best practice storage requirements expressed as an application instance associated with each of the one or more applications, and exposing the data store in application storage units associated with the one or more applications.

Abstract: A mass spectrometer for analysis of a sample 5. A laser 1 is provided to illuminate at least part of the surface of the sample 5. Laser light is conducted via an optical fibre 2 and a zoom optical system 3 to the sample. A variable ion optical system 9,10,11 is provided to extract and focus ions released from the sample 5 onto a detector 12. The optical and ion optical systems operate continuously and synchronously to vary the fields of laser illumination and view of the sample such that they are substantially confocal and equal in diameter on the surface of the sample. The sample may be a MALDI sample.

Abstract: Logical schemas are used to allow an end user the ability to access and manipulate relational database data without knowledge of the structure of the relational database. A logical schema is first created specifying which tables are available to an end user, and the relationships between columns of those tables. The logical schema defines a structure for the data fields having a master level and a plurality of detail levels. An end user may manipulate the logical schema using a graphical interface to build customized forms, reports, and queries. An end user is not required to be familiar with a database query language, such as SQL, or the structure of the relational database.